Anagrelide

Generic Name: Anagrelide hydrochloride
Dosage Form: Capsules

Rx only

Anagrelide Description

Anagrelide hydrochloride is a platelet-reducing agent. Anagrelide hydrochloride is 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one monohydrochloride monohydrate and its structural formula is:

Anagrelide has a molecular formula of C10H7Cl2N3O•HCl•H2O and a molecular weight of 310.55.

Anagrelide hydrochloride is an off-white powder. It is very slightly soluble in water and sparingly soluble in dimethyl sulfoxide and dimethylformamide.

Anagrelide hydrochloride capsules are available, for oral administration, containing 0.5 mg or 1 mg of Anagrelide base (as Anagrelide hydrochloride) and the following inactive ingredients: anhydrous lactose, black iron oxide, crospovidone, D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, FD&C Blue #2 Aluminum Lake, FD&C Red #40 Aluminum Lake, gelatin, magnesium stearate, microcrystalline cellulose, n-butyl alcohol, povidone, propylene glycol, SD-45 alcohol, SDA 3A alcohol, shellac glaze, sodium lauryl sulfate and titanium dioxide.

Anagrelide - Clinical Pharmacology

The mechanism by which Anagrelide reduces blood platelet count is still under investigation. Studies in patients support a hypothesis of dose-related reduction in platelet production resulting from a decrease in megakaryocyte hypermaturation. In blood withdrawn from normal volunteers treated with Anagrelide, a disruption was found in the postmitotic phase of megakaryocyte development and a reduction in megakaryocyte size and ploidy. At therapeutic doses, Anagrelide does not produce significant changes in white cell counts or coagulation parameters, and may have a small, but clinically insignificant effect on red cell parameters. Anagrelide inhibits cyclic AMP phosphodiesterase III (PDEIII). PDEIII inhibitors can also inhibit platelet aggregation. However, significant inhibition of platelet aggregation is observed only at doses of Anagrelide higher than those required to reduce platelet count.

Following oral administration of 14C-Anagrelide in people, more than 70% of radioactivity was recovered in urine. Based on limited data, there appears to be a trend toward dose linearity between doses of 0.5 mg and 2 mg. At fasting and at a dose of 0.5 mg of Anagrelide, the plasma half-life is 1.3 hours. The available plasma concentration time data at steady state in patients showed that Anagrelide does not accumulate in plasma after repeated administration.

Two major metabolites have been identified (RL603 and 3-hydroxy Anagrelide).

Pharmacokinetic data obtained from healthy volunteers comparing the pharmacokinetics of Anagrelide in the fed and fasted states showed that administration of a 1 mg dose of Anagrelide with food decreased the Cmax by 14%, but increased the AUC by 20%.

Pharmacokinetic information for pediatric patients is approved for Shire Pharmaceutical Development Incorporated"s Anagrelide capsules. However, due to Shire"s marketing exclusivity rights, this drug product is not labeled with that pediatric pharmacokinetic information.

A Pharmacokinetic study at a single dose of 1 mg Anagrelide in subjects with severe renal impairment (creatinine clearance < 30 mL/min) showed no significant effects on the pharmacokinetics of Anagrelide. A pharmacokinetic study at a single dose of 1 mg Anagrelide in subjects with moderate hepatic impairment showed an 8-fold increase in total exposure (AUC) to Anagrelide.

Clinical Studies

A total of 942 patients with myeloproliferative disorders including 551 patients with Essential Thrombocythemia (ET), 117 patients with Polycythemia Vera (PV), 178 patients with Chronic Myelogenous Leukemia (CML), and 96 patients with other myeloproliferative disorders (OMPD), were treated with Anagrelide in three clinical trials. Patients with OMPD included 87 patients who had Myeloid Metaplasia with Myelofibrosis (MMM), and 9 patients who had unknown myeloproliferative disorders.

Clinical Studies: Patients with ET, PV, CML, or MMM were diagnosed based on the following criteria:

* Diagnosis positive if A1, A2, and A3 present; or, if no splenomegaly, diagnosis is positive if A1 and A2 are present with any two of B1, B2, or B3.
ET Platelet count ≥ 900,000/µL on two determinations Profound megakaryocytic hyperplasia in bone marrow Absence of Philadelphia chromosome Normal red cell mass Normal serum iron and ferritin and normal marrow iron stores                        CML Persistent granulocyte count ≥ 50,000/µL without evidence of infection Absolute basophil count ≥ 100/µL Evidence for hyperplasia of the granulocytic line in the bone marrow Philadelphia chromosome is present Leucocyte alkaline phophatase ≤ lower limit of the laboratory normal range	PV* A1 Increased red cell mass A2 Normal arterial oxygen saturation A3 Splenomegaly B1 Platelet count ≥ 400,000/µL, in absence of iron deficiency or bleeding B2 Leucocytosis (≥ 12,000/µL, in the absence of infection) B3 Elevated leucocyte alkaline phosphatase B4 Elevated Serum B12	MMM Myelofibrotic (hypocellular, fibrotic) bone marrow Prominent megakaryocytic metaplasia in bone marrow Splenomegaly Moderate to severe normochromic normocytic anemia White cell count may be variable;(80,000 to 100,000/µL) Increased platelet count Variable red cell mass; teardrop poikilocytes Normal to high leucocyte alkaline phosphatase Absence of Philadelphia chromosome

Patients were enrolled in clinical trials if their platelet count was ≥ 900,000/µL on two occasions or ≥ 650,000/µL on two occasions with documentation of symptoms associated with thrombocythemia.

The mean duration of Anagrelide therapy for ET, PV, CML, and OMPD patients was 65, 67, 40, and 44 weeks, respectively; 23% of patients received treatment for 2 years. Patients were treated with Anagrelide starting at doses of 0.5 to 2 mg every 6 hours. The dose was increased if the platelet count was still high, but to no more than 12 mg each day. Efficacy was defined as reduction of platelet count to or near physiologic levels (150,000 to 400,000/µL). The criteria for defining subjects as "responders" were reduction in platelets for at least 4 weeks to ≤ 600,000/µL, or by at least 50% from baseline value. Subjects treated for less than 4 weeks were not considered evaluable. The results are depicted graphically below:

Patients with Thrombocythemia Secondary to Myeloproliferative Disorders:
Mean Platelet Count During Anagrelide Therapy

		Time on Treatment
		Weeks				Years
	Baseline	4	12	24	48	2	3	4
* × 103/µL † Nine hundred and forty-two subjects with myeloproliferative disorders were enrolled in three research studies. Of those, 923 had platelet counts over the duration of the studies.
Mean*	1131	683	575	526	484	460	437	457
N	923†	868	814	662	530	407	207	55

Anagrelide was effective in phlebotomized patients as well as in patients treated with other concomitant therapies including hydroxyurea, aspirin, interferon, radioactive phosphorus, and alkylating agents.

Indications and Usage for Anagrelide

Anagrelide hydrochloride capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events (see CLINICAL STUDIES, DOSAGE AND ADMINISTRATION).

Contraindications

Anagrelide is contraindicated in patients with severe hepatic impairment. Exposure to Anagrelide is increased 8-fold in patients with moderate hepatic impairment (see CLINICAL PHARMACOLOGY). Use of Anagrelide in patients with severe hepatic impairment has not been studied. (See also WARNINGS: Hepatic Impairment.)

Warnings

Cardiovascular

Anagrelide should be used with caution in patients with known or suspected heart disease, and only if the potential benefits of therapy outweigh the potential risks. Because of the positive inotropic effects and side-effects of Anagrelide, a pre-treatment cardiovascular examination is recommended along with careful monitoring during treatment. In humans, therapeutic doses of Anagrelide may cause cardiovascular effects, including vasodilation, tachycardia, palpitations, and congestive heart failure.

Hepatic

Exposure to Anagrelide is increased 8-fold in patients with moderate hepatic impairment (see CLINICAL PHARMACOLOGY). Use of Anagrelide in patients with severe hepatic impairment has not been studied. The potential risks and benefits of Anagrelide therapy in a patient with mild and moderate impairment of hepatic function should be assessed before treatment is commenced. In patients with moderate hepatic impairment, dose reduction is required and patients should be carefully monitored for cardiovascular effects (see DOSAGE AND ADMINISTRATION for specific dosing recommendations).

Precautions

Laboratory Tests

Anagrelide therapy requires close clinical supervision of the patient. While the platelet count is being lowered (usually during the first two weeks of treatment), blood counts (hemoglobin, white blood cells), liver function (SGOT, SGPT) and renal function (serum creatinine, BUN) should be monitored.

In 9 subjects receiving a single 5 mg dose of Anagrelide, standing blood pressure fell an average of 22/15 mm Hg, usually accompanied by dizziness. Only minimal changes in blood pressure were observed following a dose of 2 mg.

Cessation of Anagrelide Treatment

In general, interruption of Anagrelide treatment is followed by an increase in platelet count. After sudden stoppage of Anagrelide therapy, the increase in platelet count can be observed within four days.

Drug Interactions

Limited PK and/or PD studies investigating possible interactions between Anagrelide and other medicinal products have been conducted. In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of Anagrelide, nor does Anagrelide affect the PK properties of digoxin or warfarin.

Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with Anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol. There is no clinical evidence to suggest that Anagrelide interacts with any of these compounds.

An in vivo interaction study in humans demonstrated that a single 1 mg dose of Anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated. There was no effect on bleeding time, PT or aPTT. No clinically relevant pharmacokinetic interactions between Anagrelide and acetylsalicylic acid were observed. In that same study, aspirin alone produced a marked inhibition in platelet aggregation ex vivo. Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.

Anagrelide is metabolized at least in part by CYP1A2. It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of Anagrelide. Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other co-administered medicinal products sharing that clearance mechanism e.g., theophylline.

Anagrelide is an inhibitor of cyclic AMP PDE III. The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by Anagrelide.

There is a single case report which suggests that sucralfate may interfere with Anagrelide absorption.

Food has no clinically significant effect on the bioavailability of Anagrelide.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term studies in animals have been performed to evaluate carcinogenic potential of Anagrelide hydrochloride. Anagrelide hydrochloride was not genotoxic in the Ames test, the mouse lymphoma cell (L5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Anagrelide hydrochloride at oral doses up to 240 mg/kg/day (1,440 mg/m2/day, 195 times the recommended maximum human dose based on body surface area) was found to have no effect on fertility and reproductive performance of male rats. However, in female rats, at oral doses of 60 mg/kg/day (360 mg/m2/day, 49 times the recommended maximum human dose based on body surface area) or higher, it disrupted implantation when administered in early pregnancy and retarded or blocked parturition when administered in late pregnancy.

Pregnancy

Pregnancy Category C: Teratogenic Effects

Teratology studies have been performed in pregnant rats at oral doses up to 900 mg/kg/day (5,400 mg/m2/day, 730 times the recommended maximum human dose based on body surface area) and in pregnant rabbits at oral doses up to 20 mg/kg/day (240 mg/m2/day, 32 times the recommended maximum human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to Anagrelide hydrochloride.

Nonteratogenic Effects

A fertility and reproductive performance study performed in female rats revealed that Anagrelide hydrochloride at oral doses of 60 mg/kg/day (360 mg/m2/day, 49 times the recommended maximum human dose based on body surface area) or higher disrupted implantation and exerted adverse effect on embryo/fetal survival.

A perinatal and postnatal study performed in female rats revealed that Anagrelide hydrochloride at oral doses of 60 mg/kg/day (360 mg/m2/day, 49 times the recommended maximum human dose based on body surface area) or higher produced delay or blockage of parturition, deaths of nondelivering pregnant dams and their fully developed fetuses, and increased mortality in the pups born.

Five women became pregnant while on Anagrelide treatment at doses of 1 to 4 mg/day. Treatment was stopped as soon as it was realized that they were pregnant. All delivered normal, healthy babies. There are no adequate and well-controlled studies in pregnant women. Anagrelide hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Anagrelide is not recommended in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Women of childbearing potential should be instructed that they must not be pregnant and that they should use contraception while taking Anagrelide. Anagrelide may cause fetal harm when administered to a pregnant woman.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reaction in nursing infants from Anagrelide hydrochloride, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Myeloproliferative disorders are uncommon in pediatric patients and limited data are available in this population.

Anagrelide had been used successfully in 12 pediatric patients (age range 6.8 to 17.4 years; 6 male and 6 female), including 8 patients with ET, 2 patients with CML, 1 patient with PV, and 1 patient with OMPD. Patients were started on therapy with 0.5 mg q.i.d. up to a maximum daily dose of 10 mg. The median duration of treatment was 18.1 months with a range of 3.1 to 92 months. Three patients received treatment for greater than three years. Other adverse events reported in spontaneous reports and literature reviews include anemia, cutaneous photosensitivity and elevated leukocyte count.

Pharmacokinetic/pharmacodynamic study information for pediatric patients is approved for Shire Pharmaceutical Development Incorporated"s Anagrelide capsules. However, due to Shire"s marketing exclusivity rights, this drug product is not labeled with that pediatric pharmacokinetic/pharmacodynamic information.

Geriatric Use

Of the total number of subjects in clinical studies of Anagrelide, 42.1% were 65 years and over, while 14.9% were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Adverse Reactions

Analysis of the adverse events in a population consisting of 942 patients in 3 clinical studies diagnosed with myeloproliferative diseases of varying etiology (ET: 551; PV: 117; OMPD: 274) has shown that all disease groups have the same adverse event profile. While most reported adverse events during Anagrelide therapy have been mild in intensity and have decreased in frequency with continued therapy, serious adverse events were reported in these patients. These include the following: congestive heart failure, myocardial infarction, cardiomyopathy, cardiomegaly, complete heart block, atrial fibrillation, cerebrovascular accident, pericarditis, pericardial effusion, pleural effusion, pulmonary infiltrates, pulmonary fibrosis, pulmonary hypertension, pancreatitis, gastric/duodenal ulceration, and seizure.

Of the 942 patients treated with Anagrelide for a mean duration of approximately 65 weeks, 161 (17%) were discontinued from the study because of adverse events or abnormal laboratory test results. The most common adverse events for treatment discontinuation were headache, diarrhea, edema, palpitation, and abdominal pain. Overall, the occurrence rate of all adverse events was 17.9 per 1,000 treatment days. The occurrence rate of adverse events increased at higher dosages of Anagrelide.

The most frequently reported adverse reactions to Anagrelide (in 5% or greater of 942 patients with myeloproliferative disease) in clinical trials were:

Headache	43.5%
Palpitations	26.1%
Diarrhea	25.7%
Asthenia	23.1%
Edema, other	20.6%
Nausea	17.1%
Abdominal Pain	16.4%
Dizziness	15.4%
Pain, other	15.0%
Dyspnea	11.9%
Flatulence	10.2%
Vomiting	9.7%
Fever	8.9%
Peripheral Edema	8.5%
Rash, including urticaria	8.3%
Chest Pain	7.8%
Anorexia	7.7%
Tachycardia	7.5%
Pharyngitis	6.8%
Malaise	6.4%
Cough	6.3%
Paresthesia	5.9%
Back Pain	5.9%
Pruritus	5.5%
Dyspepsia	5.2%

Adverse events with an incidence of 1% to < 5% included:

Body as a Whole System: Flu symptoms, chills, photosensitivity.

Cardiovascular System: Arrhythmia, hemorrhage, hypertension, cardiovascular disease, angina pectoris, heart failure, postural hypotension, thrombosis, vasodilatation, migraine, syncope.

Digestive System: Constipation, GI distress, GI hemorrhage, gastritis, melena, aphthous stomatitis, eructation.

Hemic and Lymphatic System: Anemia, thrombocytopenia, ecchymosis, lymphadenopathy.

Platelet counts below 100,000/µL occurred in 84 patients (ET: 35; PV: 9; OMPD: 40), reduction below 50,000/µL occurred in 44 patients (ET: 7; PV: 6; OMPD: 31) while on Anagrelide therapy. Thrombocytopenia promptly recovered upon discontinuation of Anagrelide.

Hepatic System: Elevated liver enzymes were observed in 3 patients (ET: 2; OMPD: 1) during Anagrelide therapy.

Musculoskeletal System: Arthralgia, myalgia, leg cramps.

Nervous System: Depression, somnolence, confusion, insomnia, nervousness, amnesia.

Nutritional Disorders: Dehydration.

Respiratory System: Rhinitis, epistaxis, respiratory disease, sinusitis, pneumonia, bronchitis, asthma.

Skin and Appendages System: Skin disease, alopecia.

Special Senses: Amblyopia, abnormal vision, tinnitus, visual field abnormality, diplopia.

Urogenital System: Dysuria, hematuria.

Renal abnormalities occurred in 15 patients (ET: 10; PV: 4; OMPD: 1). Six ET, 4 PV and 1 with OMPD experienced renal failure (approximately 1%) while on Anagrelide treatment; in 4 cases, the renal failure was considered to be possibly related to Anagrelide treatment. The remaining 11 were found to have pre-existing renal impairment. Doses ranged from 1.5 to 6 mg/day, with exposure periods of 2 to 12 months. No dose adjustment was required because of renal insufficiency.

The adverse event profile for patients in three clinical trials on Anagrelide therapy (in 5% or greater of 942 patients with myeloproliferative diseases) is shown in the following bar graph:
 

All Patients with Myeloproliferative Disease (N=942)

Overdosage

Acute Toxicity and Symptoms

Single oral doses of Anagrelide hydrochloride at 2,500, 1,500 and 200 mg/kg in mice, rats and monkeys, respectively, were not lethal. Symptoms of acute toxicity were: decreased motor activity in mice and rats and softened stools and decreased appetite in monkeys.

There are no reports of overdosage with Anagrelide hydrochloride. Platelet reduction from Anagrelide therapy is dose-related; therefore, thrombocytopenia, which can potentially cause bleeding, is expected from overdosage. Should overdosage occur, cardiac and central nervous system toxicity can also be expected.

Management and Treatment

In case of overdosage, close clinical supervision of the patient is required; this especially includes monitoring of the platelet count for thrombocytopenia. Dosage should be decreased or stopped, as appropriate, until the platelet count returns to within the normal range.

Anagrelide Dosage and Administration

Treatment with Anagrelide hydrochloride capsules should be initiated under close medical supervision. The recommended starting dosage of Anagrelide hydrochloride capsules is 0.5 mg q.i.d. or 1 mg b.i.d., which should be maintained for at least one week. Dosage should then be adjusted to the lowest effective dosage required to reduce and maintain platelet count below 600,000/µL, and ideally to the normal range. The dosage should be increased by not more than 0.5 mg/day in any one week. Dosage should not exceed 10 mg/day or 2.5 mg in a single dose (see PRECAUTIONS).

Dosing information for pediatric patients is approved for Shire Pharmaceutical Development Incorporated"s Anagrelide capsules. However, due to Shire"s marketing exclusivity rights, this drug product is not labeled with that pediatric dosing information.

There are no special requirements for dosing the geriatric population.

It is recommended that patients with moderate hepatic impairment start Anagrelide therapy at a dose of 0.5 mg/day and be maintained for a minimum of one week with careful monitoring of cardiovascular effects. The dosage increment must not exceed more than 0.5 mg/day in any one-week. The potential risks and benefits of Anagrelide therapy in a patient with mild and moderate impairment of hepatic function should be assessed before treatment is commenced. Use of Anagrelide in patients with severe hepatic impairment has not been studied. Use of Anagrelide in patients with severe hepatic impairment is contraindicated (see CONTRAINDICATIONS).

To monitor the effect of Anagrelide and prevent the occurrence of thrombocytopenia, platelet counts should be performed every two days during the first week of treatment and at least weekly thereafter until the maintenance dosage is reached.

Typically, platelet count begins to respond within 7 to 14 days at the proper dosage. The time to complete response, defined as platelet count ≤ 600,000/µL, ranged from 4 to 12 weeks. Most patients will experience an adequate response at a dose of 1.5 to 3 mg/day. Patients with known or suspected heart disease, renal insufficiency, or hepatic dysfunction should be monitored closely.

How is Anagrelide Supplied

Anagrelide Hydrochloride Capsules are available containing 0.5 mg or 1 mg of Anagrelide base (as Anagrelide hydrochloride).

The 0.5 mg capsule is a hard-shell gelatin capsule with a light gray opaque cap and a coral opaque body axially printed with MYLAN over 6868 in black ink on both the cap and the body. The capsule is filled with white to off-white powder. They are available as follows:

NDC 0378-6868-01
bottles of 100 capsules

NDC 0378-6868-05
bottles of 500 capsules

The 1 mg capsule is a hard-shell gelatin capsule with a light gray opaque cap and an aqua blue opaque body axially printed with MYLAN over 6869 in black ink on both the cap and the body. The capsule is filled with white to off-white powder. They are available as follows:

NDC 0378-6869-01
bottles of 100 capsules

NDC 0378-6869-05
bottles of 500 capsules

Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]
Protect from light.

Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

Mylan Pharmaceuticals Inc.
Morgantown, WV 26505

REV MARCH 2005
ANAG:R2

Anagrelide Hydrochloride (Anagrelide Hydrochloride)

PRODUCT INFO Product Code 0378-6868 Dosage Form CAPSULE Route Of Administration ORAL DEA Schedule

INGREDIENTS Name (Active Moiety) Type Strength Anagrelide Hydrochloride (Anagrelide) Active 0.5 MILLIGRAM  In 1 CAPSULE anhydrous lactose Inactive   black iron oxide Inactive   crospovidone Inactive   D&C Yellow #10 Aluminum Lake Inactive   FD&C Blue #1 Aluminum Lake Inactive   FD&C Blue #2 Aluminum Lake Inactive   FD&C Red #40 Aluminum Lake Inactive   gelatin Inactive   magnesium stearate Inactive   microcrystalline cellulose Inactive   n-butyl alcohol Inactive   povidone Inactive   propylene glycol Inactive   SD-45 alcohol Inactive   SDA 3A alcohol Inactive   shellac glaze Inactive   sodium lauryl sulfate Inactive   titanium dioxide Inactive

IMPRINT INFORMATION Characteristic Appearance Characteristic Appearance Color GRAY (Light-Gray) , PINK (Coral Opaque) Score 1 Shape CAPSULE Symbol false Imprint Code MYLAN;6868 Coating false Size 12mm

PACKAGING # NDC Package Description Multilevel Packaging 1 0378-6868-01 100 CAPSULE In 1 BOTTLE, PLASTIC None 2 0378-6868-05 500 CAPSULE In 1 BOTTLE, PLASTIC None

Anagrelide Hydrochloride (Anagrelide Hydrochloride)

PRODUCT INFO Product Code 0378-6869 Dosage Form CAPSULE Route Of Administration ORAL DEA Schedule

INGREDIENTS Name (Active Moiety) Type Strength Anagrelide Hydrochloride (Anagrelide) Active 1 MILLIGRAM  In 1 CAPSULE anhydrous lactose Inactive   black iron oxide Inactive   crospovidone Inactive   D&C Yellow #10 Aluminum Lake Inactive   FD&C Blue #1 Aluminum Lake Inactive   FD&C Blue #2 Aluminum Lake Inactive   FD&C Red #40 Aluminum Lake Inactive   gelatin Inactive   magnesium stearate Inactive   microcrystalline cellulose Inactive   n-butyl alcohol Inactive   povidone Inactive   propylene glycol Inactive   SD-45 alcohol Inactive   SDA 3A alcohol Inactive   shellac glaze Inactive   sodium lauryl sulfate Inactive   titanium dioxide Inactive

IMPRINT INFORMATION Characteristic Appearance Characteristic Appearance Color GRAY (Light-Gray) , BLUE (Blue Opaque) Score 1 Shape CAPSULE Symbol false Imprint Code MYLAN;6869 Coating false Size 12mm

PACKAGING # NDC Package Description Multilevel Packaging 1 0378-6869-01 100 CAPSULE In 1 BOTTLE, PLASTIC None 2 0378-6869-05 500 CAPSULE In 1 BOTTLE, PLASTIC None

Revised: 01/2007